AYTU BIOPHARMA, INC
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
AYTU$1.81+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, June 30, 2025 | 8,976,913 | $1 | $352,500 | $(333,535) | $18,966 |
| Stock-based compensation expense | — | — | 114 | — | 114 |
| Issuance of common stock from exercise of warrants | 935,000 | — | 2,126 | — | 2,126 |
| Net income | — | — | — | 1,965 | 1,965 |
| Balances, September 30, 2025 | 9,911,913 | 1 | 354,740 | (331,570) | 23,171 |
| Stock-based compensation expense | 271,295 | — | 283 | — | 283 |
| Issuance of common stock from exercise of warrants | 550,000 | — | 1,331 | — | 1,331 |
| Net loss | — | — | — | (10,584) | (10,584) |
| Balances, December 31, 2025 | 10,733,208 | 1 | 356,354 | (342,154) | 14,201 |
| Stock-based compensation expense | — | — | 148 | — | 148 |
| Reclassification of derivative warrant liabilities to equity | — | — | 26,412 | — | 26,412 |
| Net loss | — | — | — | (5,618) | (5,618) |
| Balances, March 31, 2026 | 10,733,208 | $1 | $382,914 | $(347,772) | $35,143 |
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, June 30, 2024 | 5,972,638 | $1 | $347,688 | $(319,973) | $27,716 |
| Stock-based compensation expense | 564 | — | 173 | — | 173 |
| Issuance of common stock from exercise of warrants | 176,000 | — | 463 | — | 463 |
| Net income | — | — | — | 1,474 | 1,474 |
| Balances, September 30, 2024 | 6,149,202 | 1 | 348,324 | (318,499) | 29,826 |
| Stock-based compensation expense | 20,479 | — | 151 | — | 151 |
| Net income | — | — | — | 788 | 788 |
| Balances, December 31, 2024 | 6,169,681 | 1 | 348,475 | (317,711) | 30,765 |
| Stock-based compensation expense | 481 | — | 139 | — | 139 |
| Net income | — | — | — | 3,994 | 3,994 |
| Balances, March 31, 2025 | 6,170,162 | $1 | $348,614 | $(313,717) | $34,898 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.